ArticleOdontology2026
Effect of vitamins A/C primed human gingival mesenchymal stem/progenitor cells in preventing medication-related osteonecrosis of extraction socket: an animal study.
Article in Odontology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Human gingival mesenchymal stem/progenitor cells (hGMSCs) exert remarkable tissue regeneration properties. A combination of vitamins C and A at specified concentrations enhanced cellular dedifferentiation and multipotency of hGMSCs. To our knowledge, vitamins A/C-primed hGMSCs in the prevention of medication-related osteonecrosis of the jaw (MRONJ) have not been investigated. Thus, this study evaluated the impact of vitamins A/C in pluripotency-inductive concentrations on the regenerative/reparative potential of hGMSCs in preventing MRONJ development in rats. Thirty albino rats (n = 10/group) were administered zoledronic acid and dexamethasone three times a week for 4 weeks. The upper first molar was extracted 2 weeks following the first administration. Immediately after extraction, rats received normal saline (group Ι), hGMSCs (group ΙΙ), and hGMSCs primed with vitamins A/C (group ΙΙΙ). Rats were euthanized 2 and 4 weeks after extraction. The maxillae were analyzed using dual-energy X-ray absorptiometry, histologically, histomorphometrically, and by quantitative real-time polymerase chain reaction analysis. Groups II and III displayed elevated bone mineral density, with a significant rise in group ΙΙΙ relative to group ΙΙ at 4 weeks. Histomorphometrically, groups II and III revealed an elevation in area percentage of newly generated bone, with a significant rise in group ΙΙΙ at both time intervals. Gene expression of transforming growth factor-β1 (TGF-β1) and runt-related transcription factor 2 (Runx2) presented a significant elevation in groups II and III, with a significant rise in group ΙΙΙ at both time intervals. In conclusion, vitamins A/C-primed hGMSCs at the tested pluripotency-inductive concentrations prevented MRONJ development, primarily through encouraging wound healing and bone repair in the extraction sockets of rats.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.